---
title: "Clinical Chemistry"
order: 4
category: "Clinical Pathology"
---

# Clinical Chemistry

## Overview

Clinical chemistry is the branch of laboratory medicine concerned with the analysis of body fluids for diagnostic and therapeutic purposes. It focuses on measuring chemical components in blood, urine, cerebrospinal fluid, and other biological specimens to assess organ function, diagnose disease, monitor treatment, and evaluate metabolic status. Clinical chemistry encompasses electrolytes, enzymes, proteins, lipids, hormones, drugs, and other analytes using automated analyzers and specialized techniques.

### Scope of Practice
- Routine chemistry panels (comprehensive metabolic panel, basic metabolic panel)
- Specialized testing (cardiac markers, tumor markers, therapeutic drugs)
- Endocrine function assessment (thyroid, adrenal, reproductive hormones)
- Lipid metabolism and cardiovascular risk assessment
- Acid-base and electrolyte disorders
- Enzyme analysis for organ damage
- Therapeutic drug monitoring and toxicology

### Clinical Significance
- Assessment of renal and hepatic function
- Detection of acute coronary syndromes
- Diagnosis of metabolic and endocrine disorders
- Monitoring of chronic diseases (diabetes, dyslipidemia)
- Evaluation of electrolyte and acid-base balance
- Drug level optimization and toxicity prevention

## Basic Metabolic Panel (BMP)

### Electrolytes

#### Sodium (Na+)

##### Normal Range
- **Reference interval**: 135-145 mEq/L
- **Critical values**: <120 or >160 mEq/L
- **Major extracellular cation**

##### Physiology
- **Regulation**: Renin-angiotensin-aldosterone system (RAAS), ADH
- **Function**: Osmolality regulation, nerve/muscle function
- **Distribution**: 90% extracellular

##### Hypernatremia (Na+ >145 mEq/L)
- **Hypovolemic**: Water loss (insensible, renal, GI)
- **Euvolemic**: Diabetes insipidus, hypodipsia
- **Hypervolemic**: Cushing syndrome, hyperaldosteronism, hypertonic saline
- **Symptoms**: Thirst, confusion, seizures, coma
- **Treatment**: Free water replacement, treat underlying cause

##### Hyponatremia (Na+ <135 mEq/L)
- **Hypovolemic**: GI losses, diuretics, adrenal insufficiency
- **Euvolemic**: SIADH, hypothyroidism, psychogenic polydipsia
- **Hypervolemic**: Heart failure, cirrhosis, nephrotic syndrome
- **Symptoms**: Nausea, headache, confusion, seizures
- **Treatment**: Fluid restriction, hypertonic saline (severe), treat cause
- **Caution**: Avoid rapid correction (osmotic demyelination syndrome)

#### Potassium (K+)

##### Normal Range
- **Reference interval**: 3.5-5.0 mEq/L
- **Critical values**: <2.5 or >6.5 mEq/L
- **Major intracellular cation**

##### Physiology
- **Regulation**: Aldosterone, insulin, acid-base status
- **Function**: Membrane potential, muscle contraction
- **Distribution**: 98% intracellular

##### Hyperkalemia (K+ >5.0 mEq/L)
- **Causes**: Renal failure, acidosis, tissue breakdown, drugs (ACE inhibitors, spironolactone)
- **Pseudohyperkalemia**: Hemolysis, thrombocytosis, leukocytosis
- **ECG changes**: Peaked T waves, widened QRS, sine wave
- **Treatment**: Calcium gluconate, insulin/glucose, albuterol, dialysis
- **Life-threatening**: >6.5 mEq/L requires urgent treatment

##### Hypokalemia (K+ <3.5 mEq/L)
- **Causes**: GI losses, diuretics, hyperaldosteronism, hypomagnesemia
- **ECG changes**: U waves, T wave flattening, ST depression
- **Symptoms**: Weakness, arrhythmias, rhabdomyolysis
- **Treatment**: Oral or IV potassium replacement
- **Caution**: Correct magnesium deficiency first

#### Chloride (Cl-)

##### Normal Range
- **Reference interval**: 98-107 mEq/L
- **Major extracellular anion**

##### Physiology
- **Function**: Osmolality, acid-base balance
- **Movement**: Follows sodium and water

##### Hyperchloremia
- **Causes**: Diarrhea, RTA, normal saline infusion
- **Association**: Normal anion gap acidosis

##### Hypochloremia
- **Causes**: Vomiting, diuretics, respiratory acidosis
- **Association**: Metabolic alkalosis

#### Bicarbonate (HCO3-)

##### Normal Range
- **Reference interval**: 22-28 mEq/L
- **Primary buffer system**

##### Physiology
- **Regulation**: Kidneys (reabsorption, excretion)
- **Function**: pH maintenance

##### Elevated Bicarbonate
- **Metabolic alkalosis**: Vomiting, diuretics, Cushing syndrome
- **Compensated respiratory acidosis**

##### Decreased Bicarbonate
- **Metabolic acidosis**: Lactic acidosis, DKA, renal failure
- **Compensated respiratory alkalosis**

### Anion Gap

#### Calculation
- **Formula**: [Na+] - ([Cl-] + [HCO3-])
- **Normal range**: 8-12 mEq/L (without K+)
- **With K+**: 12-16 mEq/L

#### Elevated Anion Gap Acidosis (MUDPILES)
- **Methanol**: Formic acid accumulation
- **Uremia**: Organic acids retention
- **Diabetic ketoacidosis**: β-hydroxybutyrate, acetoacetate
- **Propylene glycol/Paraldehyde**
- **Iron/Isoniazid**
- **Lactic acidosis**: Type A (hypoxia), Type B (metformin)
- **Ethylene glycol**: Glycolic and oxalic acids
- **Salicylates**: Mixed respiratory alkalosis and metabolic acidosis

#### Normal Anion Gap Acidosis (Non-Gap)
- **Diarrhea**: Bicarbonate loss
- **Renal tubular acidosis**: Impaired acid excretion
- **Ureterosigmoidostomy**: Chloride absorption
- **Pancreatic fistula**: Bicarbonate loss
- **Carbonic anhydrase inhibitors**: Acetazolamide

### Renal Function Tests

#### Blood Urea Nitrogen (BUN)

##### Normal Range
- **Reference interval**: 7-20 mg/dL
- **End product of protein metabolism**

##### Physiology
- **Production**: Liver (urea cycle)
- **Elimination**: Renal excretion
- **Reabsorption**: Passive, increased with dehydration

##### Increased BUN
- **Prerenal**: Dehydration, heart failure, GI bleeding
- **Renal**: Acute kidney injury, chronic kidney disease
- **Postrenal**: Urinary obstruction
- **Increased production**: High protein diet, steroids, tissue breakdown

##### Decreased BUN
- **Liver disease**: Decreased urea production
- **Malnutrition**: Decreased protein intake
- **Overhydration**: Dilutional

#### Creatinine

##### Normal Range
- **Reference interval**: 0.6-1.2 mg/dL (varies by age, sex, muscle mass)
- **More specific marker of renal function than BUN**

##### Physiology
- **Production**: Muscle creatine metabolism (constant rate)
- **Elimination**: Glomerular filtration (minimal tubular handling)
- **Factors**: Age, sex, race, muscle mass

##### Increased Creatinine
- **Acute kidney injury**: Rapid rise
- **Chronic kidney disease**: Gradual rise
- **Rhabdomyolysis**: Muscle breakdown
- **Drugs**: Trimethoprim, cimetidine (compete for secretion)

##### BUN/Creatinine Ratio
- **Normal**: 10:1 to 20:1
- **Ratio >20**: Prerenal azotemia, GI bleeding, high protein intake
- **Ratio <10**: Liver disease, malnutrition, SIADH

#### Estimated Glomerular Filtration Rate (eGFR)

##### Calculation
- **CKD-EPI equation**: Most accurate
- **MDRD equation**: Previously standard
- **Cockroft-Gault**: Estimates creatinine clearance
- **Variables**: Age, sex, race, serum creatinine

##### CKD Stages
- **Stage 1**: GFR ≥90 mL/min/1.73m² (kidney damage with normal GFR)
- **Stage 2**: GFR 60-89 mL/min/1.73m² (mild decrease)
- **Stage 3a**: GFR 45-59 mL/min/1.73m² (mild-moderate decrease)
- **Stage 3b**: GFR 30-44 mL/min/1.73m² (moderate-severe decrease)
- **Stage 4**: GFR 15-29 mL/min/1.73m² (severe decrease)
- **Stage 5**: GFR <15 mL/min/1.73m² (kidney failure)

### Glucose

#### Normal Range
- **Fasting**: 70-100 mg/dL
- **Random**: <140 mg/dL
- **2-hour OGTT**: <140 mg/dL

#### Diabetes Diagnostic Criteria
- **Fasting glucose**: ≥126 mg/dL (on two occasions)
- **Random glucose**: ≥200 mg/dL with symptoms
- **2-hour OGTT**: ≥200 mg/dL
- **Hemoglobin A1c**: ≥6.5%

#### Prediabetes
- **Impaired fasting glucose**: 100-125 mg/dL
- **Impaired glucose tolerance**: 140-199 mg/dL (2-hour OGTT)
- **Hemoglobin A1c**: 5.7-6.4%

#### Hypoglycemia
- **Definition**: <70 mg/dL
- **Symptoms**: Tremor, palpitations, sweating, confusion
- **Severe**: <54 mg/dL
- **Causes**: Insulin/sulfonylureas, insulinoma, sepsis, liver failure

## Comprehensive Metabolic Panel (CMP)

### Hepatic Function Tests

#### Aminotransferases

##### Alanine Aminotransferase (ALT)

- **Normal range**: 7-56 U/L
- **Location**: Primarily liver (cytoplasm)
- **Specificity**: More specific for liver injury than AST
- **Half-life**: 47 hours

##### Aspartate Aminotransferase (AST)

- **Normal range**: 10-40 U/L
- **Location**: Liver (mitochondria, cytoplasm), heart, muscle, kidney
- **Less specific**: Elevated in myocardial infarction, muscle injury
- **Half-life**: 17 hours

##### AST/ALT Ratio
- **Ratio <1**: Acute viral hepatitis, NAFLD
- **Ratio >2**: Alcoholic liver disease, cirrhosis
- **Very high levels (>1000 U/L)**: Acute viral hepatitis, drug toxicity, ischemic hepatitis

#### Alkaline Phosphatase (ALP)

##### Normal Range
- **Adults**: 30-120 U/L
- **Children/adolescents**: Higher (bone growth)
- **Pregnancy**: Increased (placental production)

##### Sources
- **Liver**: Bile duct epithelium (cholestasis)
- **Bone**: Osteoblasts (bone formation)
- **Intestine, placenta, kidney**

##### Elevated ALP
- **Hepatobiliary**: Cholestasis, bile duct obstruction, primary biliary cholangitis
- **Bone**: Paget disease, osteomalacia, fractures, bone metastases
- **Physiologic**: Pregnancy, adolescence
- **Isoenzyme analysis**: Distinguish liver vs. bone source
- **Concurrent GGT elevation**: Suggests hepatic source

#### Gamma-Glutamyl Transferase (GGT)

##### Normal Range
- **Males**: 9-50 U/L
- **Females**: 8-40 U/L

##### Clinical Utility
- **Cholestasis**: Elevated with ALP in hepatic disease
- **Alcohol**: Sensitive marker of alcohol use
- **Drug induction**: Phenytoin, barbiturates
- **Normal in bone disease**: Distinguishes from ALP elevation

#### Bilirubin

##### Metabolism
1. **Production**: Hemoglobin breakdown → unconjugated bilirubin
2. **Transport**: Albumin-bound to liver
3. **Conjugation**: Glucuronidation in hepatocytes (conjugated bilirubin)
4. **Excretion**: Bile → intestine → urobilinogen/stercobilin

##### Total Bilirubin
- **Normal range**: 0.1-1.2 mg/dL
- **Components**: Unconjugated + conjugated

##### Direct (Conjugated) Bilirubin
- **Normal range**: 0-0.3 mg/dL
- **Water-soluble**: Excreted in urine when elevated
- **Elevation**: Hepatocellular disease, biliary obstruction

##### Indirect (Unconjugated) Bilirubin
- **Calculation**: Total - direct
- **Lipid-soluble**: Not excreted in urine
- **Elevation**: Hemolysis, Gilbert syndrome, Crigler-Najjar syndrome

##### Hyperbilirubinemia Patterns
- **Unconjugated predominance**: Hemolysis, ineffective erythropoiesis, impaired conjugation
- **Conjugated predominance**: Biliary obstruction, hepatocellular disease, Dubin-Johnson, Rotor syndrome
- **Jaundice**: Clinical icterus when bilirubin >2-3 mg/dL

#### Albumin

##### Normal Range
- **Reference interval**: 3.5-5.5 g/dL
- **Major serum protein**: ~60% of total protein

##### Functions
- **Oncotic pressure**: Maintains intravascular volume
- **Transport**: Drugs, hormones, bilirubin, fatty acids
- **Synthesis**: Liver (half-life ~20 days)

##### Hypoalbuminemia
- **Decreased synthesis**: Liver disease, malnutrition
- **Increased loss**: Nephrotic syndrome, protein-losing enteropathy
- **Increased catabolism**: Inflammation, sepsis
- **Dilution**: Fluid overload
- **Clinical effects**: Edema, ascites, decreased drug binding

##### Hyperalbuminemia
- **Rare**: Dehydration (relative increase)

#### Total Protein

##### Normal Range
- **Reference interval**: 6.0-8.3 g/dL
- **Components**: Albumin + globulins

##### Globulins
- **Calculation**: Total protein - albumin
- **Normal range**: 2.0-3.5 g/dL
- **Components**: α1, α2, β, γ globulins

##### Protein Electrophoresis
- **Albumin**: 55-70%
- **α1-globulin**: α1-antitrypsin, α1-acid glycoprotein
- **α2-globulin**: Haptoglobin, α2-macroglobulin, ceruloplasmin
- **β-globulin**: Transferrin, complement
- **γ-globulin**: Immunoglobulins

##### Monoclonal Gammopathy
- **M-spike**: Narrow band in γ or β region
- **Causes**: Multiple myeloma, MGUS, Waldenström macroglobulinemia
- **Immunofixation**: Identifies immunoglobulin type

### Calcium and Phosphate

#### Calcium

##### Normal Range
- **Total calcium**: 8.5-10.5 mg/dL
- **Ionized calcium**: 4.5-5.3 mg/dL (physiologically active)
- **Protein-bound**: ~40% (primarily albumin)

##### Corrected Calcium
- **Formula**: Measured Ca + 0.8 × (4.0 - albumin)
- **Purpose**: Adjust for hypoalbuminemia

##### Hypercalcemia
- **Primary hyperparathyroidism**: Adenoma, hyperplasia
- **Malignancy**: PTHrP secretion, bone metastases
- **Vitamin D intoxication**: Excessive supplementation
- **Granulomatous disease**: Sarcoidosis, tuberculosis
- **Thiazide diuretics**: Decreased renal excretion
- **Symptoms**: "Stones, bones, groans, psychiatric overtones"
- **Severe (>14 mg/dL)**: Medical emergency

##### Hypocalcemia
- **Hypoparathyroidism**: Post-surgical, autoimmune
- **Vitamin D deficiency**: Malabsorption, inadequate intake
- **Hypomagnesemia**: Impaired PTH secretion
- **Chronic kidney disease**: Decreased 1,25-dihydroxy vitamin D
- **Acute pancreatitis**: Calcium sequestration
- **Symptoms**: Tetany, Chvostek sign, Trousseau sign, seizures

#### Phosphate

##### Normal Range
- **Reference interval**: 2.5-4.5 mg/dL
- **Inverse relationship with calcium**

##### Hyperphosphatemia
- **Renal failure**: Decreased excretion
- **Hypoparathyroidism**: Increased renal reabsorption
- **Tumor lysis syndrome**: Massive cell breakdown
- **Rhabdomyolysis**: Phosphate release

##### Hypophosphatemia
- **Refeeding syndrome**: Insulin-driven cellular uptake
- **Hyperparathyroidism**: Increased renal excretion
- **Vitamin D deficiency**: Decreased absorption
- **Respiratory alkalosis**: Cellular shift

#### Magnesium

##### Normal Range
- **Reference interval**: 1.7-2.2 mg/dL
- **Second most abundant intracellular cation**

##### Hypermagnesemia
- **Causes**: Renal failure, excessive intake (antacids, laxatives)
- **Symptoms**: Hyporeflexia, bradycardia, respiratory depression

##### Hypomagnesemia
- **Causes**: Malnutrition, alcoholism, diuretics, diarrhea
- **Symptoms**: Tetany, arrhythmias, seizures
- **Association**: Resistant hypokalemia and hypocalcemia

## Cardiac Biomarkers

### Troponins

#### Troponin I and T
- **High specificity**: Cardiac muscle
- **Peak**: 12-24 hours after MI
- **Duration**: 7-14 days
- **Sensitivity**: Superior to CK-MB

#### High-Sensitivity Troponin
- **Detection limit**: 10-100 times lower
- **Earlier detection**: Within 3 hours
- **Protocols**: 0/1-hour, 0/3-hour algorithms
- **Specificity challenges**: Elevated in non-ACS conditions

#### Interpretation
- **Acute MI**: Rise and/or fall pattern with symptoms
- **Chronic elevation**: CKD, heart failure (stable levels)
- **99th percentile**: Upper reference limit
- **Delta change**: Significant rise or fall (>20%)

### Creatine Kinase (CK)

#### Isoenzymes
- **CK-MM**: Skeletal muscle (98%)
- **CK-MB**: Cardiac muscle (2-4% of total cardiac CK)
- **CK-BB**: Brain tissue

#### CK-MB
- **Peak**: 12-24 hours after MI
- **Return to normal**: 48-72 hours
- **Relative index**: CK-MB/total CK >2.5-3%
- **Use**: Reinfarction detection (shorter duration than troponin)

### B-Type Natriuretic Peptide (BNP)

#### Physiology
- **Production**: Ventricular myocytes in response to stretch
- **Function**: Natriuresis, vasodilation, inhibits RAAS

#### Clinical Use
- **Heart failure diagnosis**: Dyspnea evaluation
- **BNP**: <100 pg/mL (unlikely HF), >400 pg/mL (likely HF)
- **NT-proBNP**: <300 pg/mL (unlikely HF), >450 pg/mL age <50, >900 pg/mL age 50-75, >1800 pg/mL age >75
- **Prognosis**: Higher levels indicate worse outcomes
- **Monitoring**: Treatment response assessment

## Lipid Panel

### Total Cholesterol
- **Desirable**: <200 mg/dL
- **Borderline high**: 200-239 mg/dL
- **High**: ≥240 mg/dL

### Low-Density Lipoprotein (LDL-C)
- **Optimal**: <100 mg/dL
- **Near optimal**: 100-129 mg/dL
- **Borderline high**: 130-159 mg/dL
- **High**: 160-189 mg/dL
- **Very high**: ≥190 mg/dL
- **Friedewald equation**: LDL = Total cholesterol - HDL - (Triglycerides/5)
- **Direct measurement**: If triglycerides >400 mg/dL

### High-Density Lipoprotein (HDL-C)
- **Low (increased risk)**: <40 mg/dL (men), <50 mg/dL (women)
- **High (protective)**: ≥60 mg/dL
- **Inverse relationship**: Higher HDL = lower cardiovascular risk

### Triglycerides
- **Normal**: <150 mg/dL
- **Borderline high**: 150-199 mg/dL
- **High**: 200-499 mg/dL
- **Very high**: ≥500 mg/dL (pancreatitis risk)
- **Fasting required**: 9-12 hours

### Non-HDL Cholesterol
- **Calculation**: Total cholesterol - HDL
- **Target**: LDL target + 30 mg/dL
- **Advantage**: Doesn't require fasting, includes VLDL

### Cardiovascular Risk Assessment
- **Framingham Risk Score**: 10-year risk calculation
- **Pooled Cohort Equations**: ASCVD risk
- **Statin benefit groups**: Primary and secondary prevention

## Endocrine Testing

### Thyroid Function Tests

#### Thyroid-Stimulating Hormone (TSH)
- **Normal range**: 0.4-4.0 mIU/L
- **First-line test**: Screening and monitoring
- **Sensitive**: Early detection of thyroid dysfunction

#### Free T4 (Thyroxine)
- **Normal range**: 0.8-1.8 ng/dL
- **Reflects**: Metabolically active hormone
- **Independent**: Not affected by binding proteins

#### Free T3 (Triiodothyronine)
- **Normal range**: 2.3-4.2 pg/mL
- **Most active**: Thyroid hormone
- **Use**: T3 toxicosis, monitoring replacement

#### Thyroid Antibodies
- **Anti-TPO**: Hashimoto thyroiditis, Graves disease
- **Anti-thyroglobulin**: Hashimoto thyroiditis
- **TSH receptor antibodies**: Graves disease

#### Interpretation Patterns
- **Primary hypothyroidism**: High TSH, low free T4
- **Primary hyperthyroidism**: Low TSH, high free T4
- **Subclinical hypothyroidism**: High TSH, normal free T4
- **Subclinical hyperthyroidism**: Low TSH, normal free T4
- **Central hypothyroidism**: Low/normal TSH, low free T4

### Adrenal Function

#### Cortisol
- **Morning cortisol**: 5-25 μg/dL (peak 6-8 AM)
- **Diurnal variation**: Lower in evening
- **Stress response**: Increases with illness

#### ACTH
- **Normal range**: 10-60 pg/mL
- **Source**: Pituitary gland
- **Regulates**: Cortisol production

#### Adrenal Insufficiency Testing
- **Basal cortisol**: <3 μg/dL suggests insufficiency
- **ACTH stimulation test**: Cosyntropin 250 μg
- **Response**: Cortisol >18-20 μg/dL at 30-60 minutes
- **Primary vs. secondary**: ACTH level distinguishes

#### Cushing Syndrome Testing
- **24-hour urine free cortisol**: Elevated
- **Late-night salivary cortisol**: Loss of diurnal variation
- **Dexamethasone suppression test**: Failure to suppress

### Reproductive Hormones

#### Testosterone
- **Total testosterone (men)**: 300-1,000 ng/dL
- **Free testosterone**: 50-210 pg/mL
- **Timing**: Morning sample (diurnal variation)
- **Hypogonadism**: Total <300 ng/dL

#### Estradiol
- **Follicular phase**: 30-100 pg/mL
- **Midcycle peak**: 100-400 pg/mL
- **Luteal phase**: 50-150 pg/mL
- **Postmenopausal**: <30 pg/mL

#### Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH)
- **Menopause**: Elevated LH and FSH
- **Ovarian failure**: High FSH, low estradiol
- **Hypogonadotropic hypogonadism**: Low LH, FSH, testosterone/estradiol

#### Prolactin
- **Normal range**: 4-25 ng/mL
- **Causes of elevation**: Prolactinoma, medications, stress
- **Macroprolactin**: False elevation, biologically inactive

## Acid-Base Balance

### Arterial Blood Gas (ABG)

#### Normal Values
- **pH**: 7.35-7.45
- **PaCO2**: 35-45 mmHg
- **PaO2**: 80-100 mmHg
- **HCO3-**: 22-28 mEq/L
- **Base excess**: -2 to +2 mEq/L
- **O2 saturation**: >95%

#### Interpretation Steps
1. **Assess pH**: Acidemia (<7.35) or alkalemia (>7.45)
2. **Determine primary disorder**: Metabolic (HCO3-) or respiratory (PaCO2)
3. **Assess compensation**: Appropriate or mixed disorder
4. **Calculate anion gap**: If metabolic acidosis
5. **Assess oxygenation**: PaO2 and A-a gradient

### Metabolic Acidosis
- **Primary change**: Decreased HCO3-
- **Compensation**: Decreased PaCO2 (hyperventilation)
- **Expected PaCO2**: 1.5 × [HCO3-] + 8 ± 2
- **Anion gap**: Classify as high or normal gap

### Metabolic Alkalosis
- **Primary change**: Increased HCO3-
- **Compensation**: Increased PaCO2 (hypoventilation)
- **Expected PaCO2**: 0.7 × ΔHCO3- + 40
- **Causes**: Vomiting, diuretics, hypokalemia, Cushing syndrome

### Respiratory Acidosis
- **Primary change**: Increased PaCO2
- **Compensation**: Increased HCO3- (renal retention)
- **Acute**: HCO3- ↑ 1 mEq/L per 10 mmHg ↑ PaCO2
- **Chronic**: HCO3- ↑ 3.5 mEq/L per 10 mmHg ↑ PaCO2
- **Causes**: COPD, hypoventilation, neuromuscular disorders

### Respiratory Alkalosis
- **Primary change**: Decreased PaCO2
- **Compensation**: Decreased HCO3- (renal excretion)
- **Acute**: HCO3- ↓ 2 mEq/L per 10 mmHg ↓ PaCO2
- **Chronic**: HCO3- ↓ 5 mEq/L per 10 mmHg ↓ PaCO2
- **Causes**: Hyperventilation, anxiety, sepsis, high altitude

### Mixed Disorders
- **Definition**: Two or more primary acid-base disturbances
- **Recognition**: Compensation exceeds expected
- **Examples**: Sepsis (respiratory alkalosis + lactic acidosis)

## Urinalysis

### Physical Examination

#### Color
- **Normal**: Yellow (urochrome)
- **Red/brown**: Hematuria, hemoglobinuria, myoglobinuria, beets
- **Orange**: Rifampin, phenazopyridine
- **Dark**: Concentrated, bilirubin, melanin

#### Clarity
- **Clear**: Normal
- **Cloudy**: Infection, crystals, contamination

#### Specific Gravity
- **Normal range**: 1.005-1.030
- **Low (<1.010)**: Dilute urine, diabetes insipidus
- **High (>1.020)**: Concentrated, dehydration, glycosuria

### Chemical Examination (Dipstick)

#### pH
- **Normal range**: 4.5-8.0
- **Acidic**: High protein diet, metabolic acidosis
- **Alkaline**: Urinary tract infection (urease-producing bacteria), RTA

#### Protein
- **Normal**: <30 mg/dL (trace)
- **Persistent proteinuria**: >150 mg/24 hours
- **Nephrotic range**: >3.5 g/24 hours
- **Causes**: Glomerular disease, overflow proteinuria, tubular dysfunction

#### Glucose
- **Normal**: Negative
- **Threshold**: >180 mg/dL serum glucose
- **Causes**: Diabetes, pregnancy, renal glycosuria

#### Ketones
- **Normal**: Negative
- **Positive**: DKA, starvation, low-carbohydrate diet
- **Detection**: Acetoacetate (not β-hydroxybutyrate)

#### Blood
- **Detects**: Hemoglobin, myoglobin, red blood cells
- **Positive with negative microscopy**: Hemoglobinuria, myoglobinuria
- **Causes**: UTI, stones, glomerulonephritis, malignancy

#### Leukocyte Esterase
- **Indicates**: Pyuria (white blood cells)
- **Sensitivity**: 75-95% for UTI

#### Nitrite
- **Indicates**: Bacteria (gram-negative, nitrate reducers)
- **Specificity**: High for UTI when positive
- **False negative**: Non-nitrate reducing bacteria, short bladder dwell time

### Microscopic Examination

#### Red Blood Cells
- **Normal**: 0-3 per HPF
- **Dysmorphic RBCs**: Glomerular origin
- **RBC casts**: Glomerulonephritis

#### White Blood Cells
- **Normal**: 0-5 per HPF
- **Pyuria**: >10 per HPF (infection, inflammation)
- **WBC casts**: Pyelonephritis, interstitial nephritis

#### Casts
- **Hyaline casts**: Normal (concentrated urine, exercise)
- **RBC casts**: Glomerulonephritis
- **WBC casts**: Pyelonephritis, interstitial nephritis
- **Granular casts**: Acute tubular necrosis
- **Waxy casts**: Chronic kidney disease

#### Crystals
- **Uric acid**: Acidic urine, gout
- **Calcium oxalate**: Ethylene glycol, hyperoxaluria
- **Struvite**: Alkaline urine, UTI
- **Cystine**: Cystinuria

## Key Points

- Clinical chemistry provides objective assessment of organ function and metabolic status
- Electrolyte disorders require evaluation of volume status and acid-base balance
- Anion gap distinguishes causes of metabolic acidosis
- Renal function assessment uses creatinine and eGFR, not BUN alone
- Liver injury patterns (hepatocellular vs. cholestatic) guide differential diagnosis
- Cardiac troponins are gold standard for myocardial infarction diagnosis
- Lipid panels assess cardiovascular risk and guide preventive therapy
- Thyroid function testing begins with TSH, then free T4 if abnormal
- Acid-base interpretation requires systematic approach and assessment of compensation
- Urinalysis provides valuable information for renal and urologic disorders

## References

1. Burtis CA, Bruns DE. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics. 8th ed. Elsevier; 2019.
2. McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2021.
3. Kaplan LA, Pesce AJ. Clinical Chemistry: Theory, Analysis, Correlation. 6th ed. Mosby; 2020.
4. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).
5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
6. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651.
7. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine. J Clin Endocrinol Metab. 2011;96(1):53-58.
8. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract. 2012;18(6):988-1028.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
10. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician. 2005;71(6):1153-1162.
